Related references
Note: Only part of the references are listed.Non-mitotic functions of polo-like kinases in cancer cells
Christopher A. Raab et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer
Tingting Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies
Mahamat Babagana et al.
MOLECULAR CARCINOGENESIS (2020)
Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
Xupeng Mu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Direct interaction between CEP85 and STIL mediates PLK4-driven directed cell migration
Yi Liu et al.
JOURNAL OF CELL SCIENCE (2020)
PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression
Lantian Tian et al.
ONCOGENE (2020)
Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors
Natalie Timme et al.
TRANSLATIONAL ONCOLOGY (2020)
Development of a Novel Cell-Permeable Protein-Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1
David J. Huggins et al.
ACS OMEGA (2020)
Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors
Ning-Yu Wang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy
Tingting Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Prolonged mitosis results in structurally aberrant and over-elongated centrioles
Dong Kong et al.
JOURNAL OF CELL BIOLOGY (2020)
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1
Asa Ehlen et al.
NATURE COMMUNICATIONS (2020)
Small molecules, big impact: 20 years of targeted therapy in oncology
Philippe L Bedard et al.
LANCET (2020)
PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma
Wenhu Li et al.
CANCER MEDICINE (2020)
Design, synthesis and biological evaluation of novel pteridinone derivatives possessing a hydrazone moiety as potent PLK1 inhibitors
Zhiwei Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma
Zhou Deng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
Wenfeng Zhang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Phosphorylation of PLK3 Is Controlled by Protein Phosphatase 6
Cecilia Aquino Perez et al.
CELLS (2020)
Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer
Yu Zeng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC
Hao Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Targeting the PLK1-FOXO1 pathway as a novel therapeutic approach for treating advanced prostate cancer
Lilia Gheghiani et al.
SCIENTIFIC REPORTS (2020)
Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib
Yusuke Yamashita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
TRIM37 controls cancer-specific vulnerability to PLK4 inhibition
Franz Meitinger et al.
NATURE (2020)
FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity
Karineh Kazazian et al.
COMMUNICATIONS BIOLOGY (2020)
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
Siyeon Park et al.
CANCER LETTERS (2020)
Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1
Celeste N. Alverez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling
Wahafu Alafate et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy
Shazi Shakil et al.
SEMINARS IN CANCER BIOLOGY (2019)
Polo-like kinases and acute leukemia
Oksana Goroshchuk et al.
ONCOGENE (2019)
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma
Youjia Han et al.
CANCER LETTERS (2019)
Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity
Ellen Watts et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate
Sara Abdelfatah et al.
ACTA PHARMACEUTICA SINICA B (2019)
Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors
Xue Zhi Zhao et al.
MOLECULES (2019)
Iron-induced oxidative stress contributes to α-synuclein phosphorylation and up-regulation via polo-like kinase 2 and casein kinase 2
Ranran Wang et al.
NEUROCHEMISTRY INTERNATIONAL (2019)
In-silico design and synthesis of N9-substituted β-Carbolines as PLK-1 inhibitors and their in-vitro/in-vivo tumor suppressing evaluation
Gomathi Priya Jeyapal et al.
BIOORGANIC CHEMISTRY (2019)
PLK4: a promising target for cancer therapy
Yi Zhao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents
Baowen Qi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Identification of novel peptidomimetics targeting the polo-box domain of polo-like kinase 1
Zhiyan Li et al.
BIOORGANIC CHEMISTRY (2019)
Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design
Yunjiang Zhou et al.
MOLECULES (2019)
A cryptic hydrophobic pocket in the polo-box domain of the polo-like kinase PLK1 regulates substrate recognition and mitotic chromosome segregation
Pooja Sharma et al.
SCIENTIFIC REPORTS (2019)
Mechanism and Regulation of Centriole and Cilium Biogenesis
David K. Breslow et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88 (2019)
Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme
Xiangping Xia et al.
PEERJ (2019)
Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold
Xiao Lv et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
Sara Abdelfatah et al.
JOURNAL OF ADVANCED RESEARCH (2019)
High PLK4 expression promotes tumor progression and induces epithelial-mesenchymal transition by regulating the Wnt/-catenin signaling pathway in colorectal cancer
Zhibin Liao et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
A combined Fisher and Laplacian score for feature selection in QSAR based drug design using compounds with known and unknown activities
Mohammad Amin Valizade Hasanloei et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2018)
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Shanshan Gu et al.
BIOESSAYS (2018)
Forkhead box D1 promotes proliferation and suppresses apoptosis via regulating polo-like kinase 2 in colorectal cancer
Tao Han et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo
Ulrike Tontsch-Grunt et al.
CANCER LETTERS (2018)
The Acidophilic Kinases PLK2 and PLK3: Structure, Substrate Targeting and Inhibition
Giorgio Cozza et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2018)
Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy
Zhaoping Pan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Design, synthesis, and biological evaluation of novel highly selective polo-like kinase 2 inhibitors based on the tetrahydropteridin chemical scaffold
Mei-Miao Zhan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Pharmacoinformatics approach for the identification of Polo-like kinase-1 inhibitors from natural sources as anti-cancer agents
Mohamed F. AlAjmi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1
Jin Gohda et al.
SCIENTIFIC REPORTS (2018)
Plk2 Loss Commonly Occurs in Colorectal Carcinomas but not Adenomas: Relationship to mTOR Signaling
Elizabeth M. Matthew et al.
NEOPLASIA (2018)
Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors
David Hymel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway
Jie Bao et al.
CELL DEATH & DISEASE (2018)
Histone Deacetylase SIRT1 Targets Plk2 to Regulate Centriole Duplication
Hongbo Ling et al.
CELL REPORTS (2018)
Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton
Karineh Kazazian et al.
CANCER RESEARCH (2017)
Targeted protein degradation by PROTACs
Taavi K. Neklesa et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Larissa Siqueira Penna et al.
PHARMACOLOGY & THERAPEUTICS (2017)
eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma
Hongcheng Zhu et al.
RADIOTHERAPY AND ONCOLOGY (2017)
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2017)
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability
Berkley E. Gryder et al.
CANCER DISCOVERY (2017)
Aurora kinases: novel therapy targets in cancers
Anqun Tang et al.
ONCOTARGET (2017)
Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC
Leona L. Pott et al.
ONCOTARGET (2017)
The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis
Zheng Fu et al.
CANCERS (2017)
Polo-like kinase 3, hypoxic responses, and tumorigenesis
Dazhong Xu et al.
CELL CYCLE (2017)
Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides
Xue Zhi Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1
Juan Sun et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
Structure-based design and SAR development of 5,6-dihydroimidazolo [1,5-f]fipteridine derivatives as novel Polo-like kinase-1 inhibitors
Andre Kiryanov et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition
Anton Henssen et al.
CLINICAL CANCER RESEARCH (2016)
The role of Plk3 in oncogenesis
C. Helmke et al.
ONCOGENE (2016)
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2)
M. V. Ramana Reddy et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Design and optimization of (3-aryl-1H-indazol-6-yl) spiro [cyclopropane-1,3′-indolin]-2′-ones as potent PLK4 inhibitors with oral antitumor efficacy
Sze-Wan Li et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer
Baochi Ou et al.
CANCER LETTERS (2016)
Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1
Angela Berg et al.
CHEMBIOCHEM (2016)
Polo-like kinase inhibitors in hematologic malignancies
Chetasi Talati et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival
Daibiao Xiao et al.
MOLECULAR CELL (2016)
eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis
Y. Cheng et al.
ONCOGENE (2016)
MicroRNA-27b up-regulated by human papillomavirus 16 E7 promotes proliferation and suppresses apoptosis by targeting polo-like kinase2 in cervical cancer
Fei Liu et al.
ONCOTARGET (2016)
Identification of indole-3-carboxylic acids as non-ATP-competitive Polo-like kinase 1 (Plk1) inhibitors
Meng Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma
Angelika Stehle et al.
CANCER LETTERS (2015)
Synthesis and biological evaluation of 2,4-diaminopyrimidines as selective Aurora A kinase inhibitors
Wen-Wen Qin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment
Xiaoqi Liu
TRANSLATIONAL ONCOLOGY (2015)
PLK1 Phosphorylates PAX3-FOXO1, the Inhibition of Which Triggers Regression of Alveolar Rhabdomyosarcoma
Verena Thalhammer et al.
CANCER RESEARCH (2015)
Small-Molecule Control of Intracellular Protein Levels through Modulation of the Ubiquitin Proteasome System
Dennis L. Buckley et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors
Juan Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Plk1 Phosphorylation of PTEN Causes a Tumor-Promoting Metabolic State
Zhiguo Li et al.
MOLECULAR AND CELLULAR BIOLOGY (2014)
Regulation of Autophosphorylation Controls PLK4 Self-Destruction and Centriole Number
Ines Cunha-Ferreira et al.
CURRENT BIOLOGY (2013)
The Discovery of PLK4 Inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as Novel Antiproliferative Agents
Radoslaw Laufer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
Anton Henssen et al.
ONCOTARGET (2013)
Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours
A. Frost et al.
CURRENT ONCOLOGY (2012)
Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer
Zhao-Xia Wang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors
Fatih Uckun et al.
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH (2011)
eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206
Yan Cheng et al.
CANCER RESEARCH (2011)
From Plk1 to Plk5 Functional evolution of Polo-like kinases
Guillermo de Carcer et al.
CELL CYCLE (2011)
PLK1 as an oncology target: current status and future potential
Campbell McInnes et al.
DRUG DISCOVERY TODAY (2011)
Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions
El Mustapha Bahassi
EXPERIMENTAL BIOLOGY AND MEDICINE (2011)
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel
Fa Liu et al.
NATURE CHEMICAL BIOLOGY (2011)
Polo-box domain: a versatile mediator of polo-like kinase function
Jung-Eun Park et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors
Ralf-Dieter Hofheinz et al.
CLINICAL CANCER RESEARCH (2010)
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Puneet Chopra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Susanne M. A. Lens et al.
NATURE REVIEWS CANCER (2010)
BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
Dorothea Rudolph et al.
CLINICAL CANCER RESEARCH (2009)
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
Sang-Moon Yun et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2009)
Polo-Like Kinase 1 Is Essential for Early Embryonic Development and Tumor Suppression
Lin-Yu Lu et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Libor Macurek et al.
NATURE (2008)
Brd4 recruits P-TER to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression
Zhiyuan Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Selectivity-determining residues in Plk1
Michael Kothe et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2007)
The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation
Shwu-Yuan Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo
Martin Steegmaier et al.
CURRENT BIOLOGY (2007)
Aurora kinases: New targets for cancer therapy
Richard D. Carvajal et al.
CLINICAL CANCER RESEARCH (2006)
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
XQ Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
